Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-w79xw Total loading time: 0 Render date: 2025-02-23T13:03:27.680Z Has data issue: false hasContentIssue false

Piribedil

Published online by Cambridge University Press:  20 February 2025

K. Ray Chaudhuri ,
Peter Jenner ,
Valentina Leta ,
Shelley Jones  and
Iro Boura
K. Ray Chaudhuri
Affiliation:
King's College London
Peter Jenner
Affiliation:
King's College London
Valentina Leta
Affiliation:
King's College London
Shelley Jones
Affiliation:
King's College London
Iro Boura
Affiliation:
St. George General Hospital of Chania, Crete, Greece
Get access

Summary

Piribedil (2-(4-piperonylpiperazin-1-yl)pyrimidine) is a non-ergot dopamine agonist with a molecular weight of 298.34 and an empirical formula of C16H18N4O2.

Type
Chapter
Information
The Movement Disorders Prescriber's Guide to Parkinson's Disease , pp. 354 - 362
Publisher: Cambridge University Press
Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Perez-Lloret, S, Rascol, O. Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. CNS Drugs 2016; 30(8): 703–717.CrossRefGoogle ScholarPubMed
Thobois, S, Lhommée, E, Klinger, H, Ardouin, C, Schmitt, E, Bichon, A, Kirstner, A, Castrioto, A, Xie, J, Fraix, V, Pelissier, P, Chabardes, S, Mertens, P, Quesada, JL, Bosson, JL, Pollak, P, Broussolle, E, Krack, P. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013: 136(Pt 5): 1568–1577.CrossRefGoogle ScholarPubMed

References

Czernecki, V, Schüpbach, M, Yaici, S, Lévy, R, Bardinet, E, Yelnik, J, Dubois, B, Agid, Y. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord 2008: 23(7): 964–969.CrossRefGoogle ScholarPubMed
Deleu, D, Northway, MG, Hanssens, Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 2002; 41(4): 261–309.CrossRefGoogle ScholarPubMed
Eggert, K, Öhlwein, C, Kassubek, J, Wolz, M, Kupsch, A, Ceballos-Baumann, A, Ehret, R, Polzer, U, Klostermann, F, Schwartz, J, Fuchs, G, Jost, W, Albert, A, Haag, A, Hermsen, A, Lohmüller, K, Kuhn, K, Wangemann, M, Hoertel, W. Influence of the nonergot dopamine agonist piribedil on vigilance in patients with Parkinson disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole. Clin Neuropharmacol 2014; 37(4): 116–122.CrossRefGoogle Scholar
Jenner, P. Parkinson’s disease: pathological mechanisms and actions of piribedil. J Neurol 1992; 239(Suppl 1): S2–S8.CrossRefGoogle ScholarPubMed
Lebrun-Frenay, C, Borg, M. Choosing the right dopamine agonist for patients with Parkinson’s disease. Curr Med Res Opin 2002; 18(4): 209–214.CrossRefGoogle ScholarPubMed
Mentenopoulos, G, Katsou, Z, Bostantjopoulou, S, Logothetis, J. Piribedil therapy in Parkinson’s disease. Use of the drug in the retard form.Clin Neuropharmacol 1989; 12(1): 23–28.CrossRefGoogle ScholarPubMed
Millan, MJ. From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson’s disease. Pharmacol Ther 2010; 128(2): 229–273.CrossRefGoogle Scholar
Nagaraja, D, Jayashree, S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry 2001; 158(9): 1517–1519.CrossRefGoogle ScholarPubMed
Nyholm, D. Pharmacokinetic optimisation in the treatment of Parkinson’s disease: an update. Clin Pharmacokinet 2006: 45(2): 109–136.CrossRefGoogle ScholarPubMed
Piribedil. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 4 December 2022 via www.medicinescomplete.com.Google Scholar
Rondot, P, Ziegler, M. Activity and acceptability of piribedil in Parkinson’s disease: a multicentre study. J Neurol 1992; 239(Suppl 1): S28–S34.CrossRefGoogle ScholarPubMed
Rota, S, Boura, I, Batzu, L, Titova, N, Jenner, P, Falup-Pecurariu, C, Chaudhuri, KR. ‘Dopamine agonist phobia; in Parkinson’s disease: when does it matter? Implications for non-motor symptoms and personalized medicine. Expert Rev Neurother 2020; 20(9): 953–365.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Piribedil
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.038
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Piribedil
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.038
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Piribedil
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.038
Available formats
×